Clinical Trial Update: Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lemborexant for residual insomnia in adults with major depressive disorder; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia
• Major Depressive Disorder

Drugs mentioned

• Dayvigo (lemborexant)

Snippet

Sponsor: Unity Health Toronto | Conditions: Major Depressive Disorder(MDD), Insomnia Comorbid to Psychiatric Disorder | Phase 2 | Status: NOT_YET_RECRUITING